关于华厦眼科医院集团股份有限公司 2023 年度持续督导跟踪报告 中国国际金融股份有限公司 三、公司及股东承诺事项履行情况 | 公司及股东承诺事项 | 是否履行承诺 | 未履行承诺的原因及解决措施 | | --- | --- | --- | | 1.关于股份限售的承诺 | 是 | 不适用 | | 2.关于股份减持的承诺 | 是 | 不适用 | | 3.关于同业竞争、关联交易、资金占 用方面的承诺 | 是 | 不适用 | | 4.关于稳定股价的承诺 | 是 | 不适用 | | 保荐人名称：中国国际金融股份有限公司 | 被保荐公司简称：华厦眼科 | | --- | --- | | 保荐代表人姓名：沈俊 | 联系电话：010 65051166 | | 保荐代表人姓名：赵冀 | 联系电话：010 65051166 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公 ...

Group 1: Profit Distribution and Financial Performance - The company prioritizes cash dividends as a profit distribution method, considering profitability, regulatory compliance, and operational funding needs [1][2] - The expected earnings per share for 2023 is 0.79 CNY, representing a 17.91% increase compared to 2022 [3][4] - The company has a stable cash reserve, and recent reductions in long-term loans will not significantly impact financial status or operations [5][6] Group 2: Research and Development Initiatives - The company has enhanced its R&D personnel and plans to further increase their numbers, focusing on partnerships with universities and research institutions [2][3] - Continuous investment in clinical research is aimed at improving innovation capabilities in eye disease treatment [2][3] Group 3: Corporate Governance and Compliance - The company has established a robust governance framework to ensure compliance with laws and regulations, particularly regarding related party transactions [5][6] - There are no reported investigations or compliance issues affecting the company's operations [6][7] Group 4: Shareholder Structure and Market Position - The major shareholders remain stable, and there have been no adverse effects on the company's operations due to changes in shareholder structure [6][7] - The company is committed to enhancing its ESG performance and has been disclosing ESG reports for two consecutive years [6]

证券代码：301267 证券简称：华厦眼科 公告编号：2024-029 华厦眼科医院集团股份有限公司 关于收购资产事项的进展暨完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开第三届董事会第六次会议及第三届监事会第六次会议，审议通过了《关于使 用自有资金和部分超募资金收购资产的议案》，同意公司收购厦门华厦聚信壹号 投资咨询有限公司（以下简称"聚信壹号咨询公司"）100%股权，交易金额共计 人民币 50,250.00 万元，资金来源为自有资金 31,250.00 万元及部分超募资金 19,000.00 万元。本次交易完成后，聚信壹号咨询公司将成为公司全资子公司，纳 入公司合并报表范围。上述事项具体内容详见公司分别于 2024 年 4 月 26 日、 2024 年 4 月 30 日披露于巨潮资讯网（www.cninfo.com.cn）的《关于使用自有资 金和部分超募资金收购资产的公告》（公告编号：2024-024）和《关于使用自有 资金和部分 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [3][5]. Core Views - The company has demonstrated steady revenue growth, with 2023 revenue reaching 4.013 billion yuan, a year-on-year increase of approximately 24.12%. The outpatient volume exceeded 1.86 million visits, growing about 21%, and the number of surgeries surpassed 370,000, increasing by approximately 23% [4][5]. - The growth is attributed to the recovery of cataract and other eye disease treatments, steady growth in consumer demand for ophthalmology, and an increasing proportion of high-end surgical procedures. The company adheres to a "growth through internal development and external acquisitions" strategy to enhance its national ophthalmology service network [4][5]. - The company plans to acquire 100% of Xiamen Huaxia Juxin No. 1 Investment Consulting Co., Ltd. for 503 million yuan, which indirectly controls several hospitals, including Chengdu Aidi Eye Hospital and Weishan Medical University Eye Hospital [4]. Summary by Sections Financial Performance - In 2023, the company's operating revenue was 4.013 billion yuan, with a net profit attributable to the parent company of 666 million yuan, reflecting a year-on-year increase of 29.60%. For Q1 2024, revenue was 978 million yuan, up 5.09%, and net profit was 156 million yuan, up 3.75% [4][5]. Business Strategy - The company is deepening its "integrated medical education and research" approach, establishing a mature medical education and research system, and has approved 36 new medical research projects in 2023 [4]. - The company is enhancing its service capabilities by introducing new equipment, such as the first Zeiss 3D digital navigation surgical microscope in China, and is expanding its national chain of eye hospitals, having established 57 specialized eye hospitals and 60 vision centers across 47 cities in 18 provinces and municipalities [4][5]. Future Projections - Revenue projections for 2024, 2025, and 2026 are estimated at 4.856 billion yuan, 5.851 billion yuan, and 7.022 billion yuan, respectively. The net profit attributable to the parent company is projected to be 822 million yuan, 1.007 billion yuan, and 1.227 billion yuan for the same years, with corresponding PE ratios of 26, 21, and 17 times [5].

证券研究报告 ＃＃iinndduussttrryyIIdd＃＃ 医药生物 ＃investSuggestion＃ ＃ ＃d华yCo厦mpa眼ny＃科 （301267.SZ） investSug 增持 ( 维ges持tionC）h 000009 基础眼病和消＃费tit眼le＃科均衡增长， ange＃ 不断吸收整合优质资源 ＃createTime1＃ 2024 年05月09 日 ＃市场ma数rk据etData＃ 投资要点 ＃summary＃ 日期 2024/5/8  公司发布 2023 年年报及 2024 年一季报。2023 年，公司实现营收 40.13 亿元 收盘价（元） （YOY+24.12%）；归母净利润6.66亿元（YOY+29.60%）；扣非归母净利润6.62 26.54 总股本（百万股） 亿元（YOY+22.37%）。2023Q4，公司实现营收9.10亿元（YOY+28.17%）；归母净 840.00 流通股本（百万股） 利润1.09亿元（YOY-6.57%）；扣非归母净利润0.90亿元（YOY-16.61%）。2024Q1， 328.83 净资产（百万元） 公司实现营收9.78亿元（YOY+5.09 ...

Investment Rating - The investment rating for the company is "Buy" with a target price not specified in the report [2]. Core Views - The company reported steady growth in diagnostic and treatment demand, with a robust profitability maintained [3]. - In 2023, the company achieved a revenue of 4.013 billion yuan, a year-on-year increase of 24.12%, and a net profit of 666 million yuan, up 29.6% [3]. - The company’s outpatient visits exceeded 1.86 million, a growth of 21%, and surgical procedures surpassed 370,000, increasing by approximately 23% [4]. - The company’s main business gross margin reached 49.04%, an increase of 0.88 percentage points year-on-year, with significant improvements in cataract and posterior segment business margins [5]. - The company is expanding its global ophthalmic medical service network through both organic growth and acquisitions [6]. Financial Summary - The company’s projected revenues for 2024-2026 are 4.776 billion, 5.674 billion, and 6.679 billion yuan, with year-on-year growth rates of 19.0%, 18.8%, and 17.7% respectively [7]. - The net profit forecasts for the same period are 853 million, 1.084 billion, and 1.362 billion yuan, with growth rates of 28.1%, 27.1%, and 25.7% respectively [7]. - The company’s earnings per share (EPS) are expected to be 1.02, 1.29, and 1.62 yuan per share for 2024, 2025, and 2026 respectively [7]. - The company’s total share capital is 840 million shares, with a circulating market value of approximately 8.799 billion yuan [8].

公司研 究 证 券研究 报 告 医疗服务 2024年05月09日 华 厦眼科（301267）2023年报及 2024年一季报点评 推 荐 （维持） 优势学科引领增长，外延并购落地有望增厚 目标价：31.5元 全年业绩 当前价：26.54元 事项： 华创证券研究所  4月25日，公司发布23年报和24年一季报。23年公司营业收入40.13亿元 证券分析师：郑辰 （+24.12%），归母净利润 6.66 亿元（+29.60%），扣非归母净利润 6.62 亿元 （+22.37%）。24Q1 公司收入 9.78 亿元（+5.09%），归母净利润 1.56 亿元 邮箱：zhengchen@hcyjs.com （+3.75%），扣非归母净利润1.57亿元（+6.89%）。 执业编号：S0360520110002 评论： 证券分析师：王宏雨  优势学科和优势地区持续引领增长。截至 23 年底，公司已经在 47 个城市开 邮箱：wanghongyu@hcyjs.com 设57家专科医院和60家视光中心，国内领先的眼科医疗连锁集团地位稳固。 执业编 号：S0360523080006 分业务看，2023年公司白内障、眼后段、 ...

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 38.54 CNY, down from a previous target of 51.30 CNY [1]. Core Views - The company's performance met expectations, and the upcoming external acquisitions are expected to enhance operational performance [1]. - The report maintains an "Accumulate" rating, considering the recovery in consumer healthcare and the pace of hospital acquisitions [1]. Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 40.13 billion CNY, representing a year-on-year increase of 24.12%. The net profit attributable to shareholders was 6.66 billion CNY, up 29.60% [1]. - For Q1 2024, the company reported a revenue of 9.78 billion CNY, a growth of 5.09%, and a net profit of 1.57 billion CNY, reflecting a 6.89% increase [1]. Operational Highlights - The company experienced a continuous recovery in eye disease treatments, with outpatient visits exceeding 186 million, a 21% increase year-on-year. Surgical procedures surpassed 370,000, marking a 23% growth [1]. - Revenue from cataract treatments reached 9.87 billion CNY, up 31.38%, while revenue from high-end refractive procedures also showed steady growth [1]. Acquisition Strategy - The company is expanding its network through acquisitions, planning to acquire a consulting company for 5.025 billion CNY and several eye hospitals, which is expected to enhance operational performance [1]. - As of the end of the year, the company had established 100 eye hospitals and 60 optical centers across 18 provinces and municipalities [1]. Financial Projections - The earnings per share (EPS) forecast for 2024 and 2025 has been adjusted to 0.94 CNY and 1.07 CNY, respectively, with a projected PE ratio of 41x for 2024 [1]. - The company anticipates continued revenue growth, with projected revenues of 4.785 billion CNY in 2024 and 5.295 billion CNY in 2025 [1].

华厦眼科医院集团股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 1 月 8 日 召开了第三届董事会第五次会议和第三届监事会第五次会议，审议通过了《关于 回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易的方式回购 部分公司股份，用于实施员工持股计划或股权激励。本次回购股份的资金总额不 低于 1.5 亿元且不超过 2.5 亿元（均含本数）；回购价格不超过 50.93 元/股（含 本数），回购股份实施期限自公司董事会审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 1 月 9 日、2024 年 1 月 15 日在巨潮 资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编 号：2024-003）、《回购报告书》（公告编号：2024-005）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》（以下简称"《自律监管指引第 9 号》"）等相关规定 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2024-028 华厦眼科医院集团股份有限公司 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2024 年 5 月 16 日（周四）14:00-17:00。 关于参加厦门辖区上市公司 2023 年年报业绩说明会暨 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华厦眼科医院集团股份有限公司（以下 简称"公司"）将参加由厦门证监局、厦门上市公司协会与深圳市全景网络有限 公司联合举办的"厦门辖区上市公司 2023 年年报业绩说明会暨投资者网上集体 接待日活动"，现将相关事项公告如下： 特此公告 华厦眼科医院集团股份有限公司董事会 2024 年 5 月 6 日 出席本次业绩说明会的人员有：公司董事陈凤国先生、财务总监陈鹭燕女士、 董事会秘书曹乃恩先生以及独立董事郑文礼先生、保荐代表人赵冀先生。 届时公司董事及高 ...